E P Acosta

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. pmc Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
    Lin Shen
    Department of Medicine, Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, Maryland 21205, USA
    Nat Med 14:762-6. 2008
  2. pmc Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    Antimicrob Agents Chemother 56:5938-45. 2012
  3. ncbi request reprint Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation
    E P Acosta
    Division of Clinical Pharmacology, The University of Alabama at Birmingham, Birmingham, Alabama, USA
    Clin Pharmacol Ther 81:867-72. 2007
  4. ncbi request reprint Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL 35294 0019, USA
    Clin Infect Dis 36:373-7. 2003
  5. ncbi request reprint Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0019, USA
    J Acquir Immune Defic Syndr 37:1358-66. 2004
  6. pmc Oseltamivir dosing for influenza infection in premature neonates
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA
    J Infect Dis 202:563-6. 2010
  7. pmc Determination of appropriate dosing of influenza drugs in pediatric patients
    E P Acosta
    Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    Clin Pharmacol Ther 88:704-7. 2010
  8. pmc Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women
    Edward P Acosta
    University of Alabama at Birmingham, Birmingham, Alabama, USA
    Antimicrob Agents Chemother 48:430-6. 2004
  9. ncbi request reprint Position paper on therapeutic drug monitoring of antiretroviral agents
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    AIDS Res Hum Retroviruses 18:825-34. 2002
  10. ncbi request reprint Pharmacokinetic enhancement of protease inhibitors
    E P Acosta
    Division of Clinical Pharmacology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 0019, USA
    J Acquir Immune Defic Syndr 29:S11-8. 2002

Research Grants

Detail Information

Publications72

  1. pmc Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
    Lin Shen
    Department of Medicine, Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, Maryland 21205, USA
    Nat Med 14:762-6. 2008
    ..Only agents with slopes >1 achieve high-level inhibition of single-round infectivity, a finding with profound implications for drug and vaccine development...
  2. pmc Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    Antimicrob Agents Chemother 56:5938-45. 2012
    ....
  3. ncbi request reprint Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation
    E P Acosta
    Division of Clinical Pharmacology, The University of Alabama at Birmingham, Birmingham, Alabama, USA
    Clin Pharmacol Ther 81:867-72. 2007
    ....
  4. ncbi request reprint Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL 35294 0019, USA
    Clin Infect Dis 36:373-7. 2003
    ....
  5. ncbi request reprint Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0019, USA
    J Acquir Immune Defic Syndr 37:1358-66. 2004
    ....
  6. pmc Oseltamivir dosing for influenza infection in premature neonates
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA
    J Infect Dis 202:563-6. 2010
    ..0 mg/kg/dose twice daily. These results provide initial guidance on dosing oseltamivir in this vulnerable population...
  7. pmc Determination of appropriate dosing of influenza drugs in pediatric patients
    E P Acosta
    Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    Clin Pharmacol Ther 88:704-7. 2010
    ..The evaluation of influenza antiviral agents in premature infants adds even more complexity. Recent advances in exposure-targeted study designs and modeling and simulations have aided in addressing some of these challenges...
  8. pmc Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women
    Edward P Acosta
    University of Alabama at Birmingham, Birmingham, Alabama, USA
    Antimicrob Agents Chemother 48:430-6. 2004
    ..These PK results suggest that SQV-RTV at 800/100 mg b.i.d. appears to be a reasonable treatment option for this population...
  9. ncbi request reprint Position paper on therapeutic drug monitoring of antiretroviral agents
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    AIDS Res Hum Retroviruses 18:825-34. 2002
    ..This position paper offers guidelines to aid clinicians who choose to incorporate TDM into the routine care of their patients...
  10. ncbi request reprint Pharmacokinetic enhancement of protease inhibitors
    E P Acosta
    Division of Clinical Pharmacology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 0019, USA
    J Acquir Immune Defic Syndr 29:S11-8. 2002
    ..Large prospective studies are needed to further advance the usefulness of therapeutic drug monitoring...
  11. ncbi request reprint Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women
    E P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham, 35294 0019, USA
    HIV Clin Trials 2:460-5. 2001
    ..To evaluate saquinavir (SQV) pharmacokinetics, tolerance, and safety in 10 HIV-infected pregnant women between 14-32 weeks gestation...
  12. pmc Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics
    E P Acosta
    Department of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL 35294 0019, USA
    Antimicrob Agents Chemother 45:2771-4. 2001
    ..We concluded that 56 days of intravenous and oral acyclovir therapy were well tolerated but had little or no effect on the clinical course of postherpetic neuralgia...
  13. pmc Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus
    Ighovwerha Ofotokun
    Department of Medicine, Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, Georgia 30303, USA
    Pharmacotherapy 28:74-81. 2008
    ..To evaluate the pharmacokinetic compatibility of a ritonavir-boosted indinavir-fosamprenavir combination among patients with human immunodeficiency virus (HIV)...
  14. ncbi request reprint Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403
    Jennifer R King
    University of Alabama at Birmingham, Birmingham, USA
    Pediatr Infect Dis J 24:880-5. 2005
    ..We tested the efficacy, tolerability and pharmacokinetics of 2 combination therapies containing an NRTI, protease inhibitors +/- a nonnucleoside reverse transcription inhibitor (NNRTI)...
  15. ncbi request reprint Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy
    Jennifer R King
    University of Alabama at Birmingham, School of Medicine, Division of Clinical Pharmacology, Birmingham, Alabama, USA
    AIDS 19:1059-63. 2005
    ..To describe the in vivo protein-binding characteristics of indinavir (IDV) in the presence of ritonavir (RTV) relative to total IDV plasma concentrations...
  16. ncbi request reprint Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1
    Edward P Acosta
    Department of Clinical Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Acquir Immune Defic Syndr 33:343-8. 2003
    ..A similar approach might be considered using a more potent regimen for patients in whom resistance to nucleosides is a major reason for therapeutic failure...
  17. ncbi request reprint Pharmacokinetic enhancement of protease inhibitor therapy
    Jennifer R King
    Division of Clinical Pharmacology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 0019, USA
    Clin Pharmacokinet 43:291-310. 2004
    ..The following manuscript will discuss the rationale for combining protease inhibitors and will review pertinent pharmacokinetic and clinical data on these combination regimens...
  18. ncbi request reprint Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients
    Jennifer R King
    Division of Clinical Pharmacology, University of Alabama at Birmingham, 35294, USA
    Pediatr Infect Dis J 22:239-44. 2003
    ..The clinical benefits of this regimen are often accompanied by increased toxicities. We report the safety and tolerance of multiple drug therapy in HIV-infected children...
  19. ncbi request reprint Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice
    Ray Y Chen
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    AIDS Res Hum Retroviruses 18:909-16. 2002
    ..We conclude that the majority of our patients in virologic failure who underwent a temporary TI recovered 90% of their baseline CD4(+) cell counts and returned to within 2-fold of their baseline VL when HAART was resumed...
  20. ncbi request reprint Concentration-controlled zidovudine therapy
    C V Fletcher
    Division of Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, USA
    Clin Pharmacol Ther 64:331-8. 1998
    ..The active moiety of nucleoside anti-HIV drugs is the intracellular anabolite. Therefore the heterogeneity in response to nucleoside agents may arise as a result of pharmacologic variability at both the systemic and cellular level...
  21. doi request reprint Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline
    J Michael Kilby
    Division of Infectious Diseases and 1917 HIV Research Clinic, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35294 2050, USA
    AIDS 22:957-62. 2008
    ..Compare the initial phases of virologic decay when acute/early and advanced HIV-infected adults are administered the same treatment regimen...
  22. doi request reprint Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease
    David W Kimberlin
    Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA
    J Infect Dis 197:836-45. 2008
    ..Intravenous ganciclovir administered for 6 weeks improves hearing outcomes in infants with symptomatic congenital cytomegalovirus (CMV) disease involving the central nervous system...
  23. pmc Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia
    Jeffrey Sa Stringer
    Schools of Medicine and Public Health, University of Alabama at Birmingham, USA
    AIDS 19:1309-15. 2005
    ..To determine the population effectiveness of a city-wide perinatal HIV prevention program...
  24. pmc Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients
    Jennifer R King
    The University of Alabama at Birmingham, Birmingham, AL, USA
    Pediatr Infect Dis J 28:159-61. 2009
    ..Our data support the current LPV/RTV dose, but EFV 350 mg/m may not be sufficient...
  25. pmc Novel methodology for antiretroviral quantitation in the female genital tract
    Chantelle Bennetto-Hood
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    HIV Clin Trials 10:193-9. 2009
    ..Challenges exist regarding antiretroviral quantitation in the female genital tract. Endocervical wicking using sterile tear flow test strips is an alternative to conventional methods due to the consistent sample volume obtained...
  26. pmc Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily
    Edward P Acosta
    University of Alabama at Birmingham, Birmingham, Alabama, USA
    Antimicrob Agents Chemother 51:3104-10. 2007
    ..Although safe and generally well tolerated, 300 mg or 400 mg atazanavir administered every 12 h did not maintain adequate plasma exposure when coadministered with rifampin...
  27. pmc Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings
    Jeffrey S A Stringer
    Schools of Medicine and Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA
    AIDS 18:939-43. 2004
    ..To assess the uptake of and adherence to nevirapine to prevent mother-to-child HIV transmission among women of unknown HIV serostatus presenting in labor. We also assessed preliminary efficacy of the approach...
  28. ncbi request reprint Duration of highly active antiretroviral therapy regimens
    Ray Y Chen
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 35294 2050, USA
    Clin Infect Dis 37:714-22. 2003
    ..6 years, and medication toxicity-associated events were the cause of one-half of discontinuations. Only a history of opportunistic infection and injection drug use were significantly associated with shorter regimen duration...
  29. pmc Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings
    Jeffrey S A Stringer
    Department of Obstetrics and Gynecology, Schools of Medicine and Public Health, University of Alabama at Birmingham, Alabama, USA
    J Acquir Immune Defic Syndr 32:506-13. 2003
    ....
  30. pmc Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine
    Jeffrey S A Stringer
    Schools of Medicine and Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA
    AIDS 17:1659-65. 2003
    ..Single-dose intrapartum and neonatal nevirapine (NVP) reduces perinatal HIV transmission and is in increasingly common use throughout the developing world...
  31. ncbi request reprint Antiretroviral pharmacokinetics in the paediatric population: a review
    Jennifer R King
    Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294 0019, USA
    Clin Pharmacokinet 41:1115-33. 2002
    ..If prevention of treatment failure continues to be the goal of antiretroviral therapy, the pharmacokinetics of antiretrovirals in children need to be assessed early in the drug development process...
  32. ncbi request reprint Detection of nevirapine in plasma using thin-layer chromatography
    Jeffrey G Dubuisson
    Division of Clinical Pharmacology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham School of Medicine, USA
    J Acquir Immune Defic Syndr 35:155-7. 2004
    ..This report describes a fast, inexpensive thin-layer chromatography (TLC) method to detect the presence of NVP in human plasma...
  33. ncbi request reprint Persistence of nevirapine in breast milk after discontinuation of treatment
    Chantelle Bennetto-Hood
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0019, USA
    Clin Infect Dis 45:391-4. 2007
    ..Nevirapine was quantifiable for up to 17 days after discontinuation of therapy; total nevirapine concentrations remained above the 90% inhibitory concentration for 6 days, and no differences were observed between breasts...
  34. ncbi request reprint Tipranavir: a novel nonpeptidic protease inhibitor of HIV
    Jennifer R King
    The University of Alabama at Birmingham, Birmingham, Alabama 35294 0019, USA
    Clin Pharmacokinet 45:665-82. 2006
    ..Therefore, this novel PI in combination with ritonavir represents an important new choice in the treatment of multiple-PI-experienced patients...
  35. ncbi request reprint Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy
    Jeff D Moore
    University of Alabama at Birmingham, Division of Clinical Pharmacology, Birmingham, AL, USA
    Antivir Ther 12:981-6. 2007
    ..Little is known about how commonly used dual-NRTI regimens affect the intracellular levels of NRTI-TPs, the active form of these drugs. This study investigates the effect of dual-NRTI therapy in intracellular NRTI-TP levels...
  36. ncbi request reprint Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers
    Jennifer R King
    PharmD, University of Alabama at Birmingham, Division of Clinical Pharmacology, 1530 3rd Avenue South, VH 116, Birmingham, AL 35294 0019, USA
    J Clin Pharmacol 47:201-8. 2007
    ..Although SQV plasma concentrations were higher when coadministered with RTV, a combination of SQV/ATV administered BID may be a viable alternative in HIV-infected, PI-naive subjects intolerant to RTV...
  37. ncbi request reprint Effects of concentration and temperature on the stability of nevirapine in whole blood and serum
    Chantelle J Bennetto
    The University of Alabama at Birmingham, School of Medicine, Division of Clinical Pharmacology, 1530 3rd Ave South, VH 116, Birmingham, AL 35294 0019, USA
    Clin Chem 50:209-11. 2004
  38. doi request reprint Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum
    Chantelle Bennetto-Hood
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0019, USA
    HIV Clin Trials 10:41-7. 2009
    ....
  39. ncbi request reprint Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube
    Jennifer R King
    Division of Clinical Pharmacology, University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, AL 35294, USA
    HIV Clin Trials 5:288-93. 2004
    ..The goal of this pilot study was to describe the pharmacokinetic characteristics of protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) when administered to HIV-infected children via g-tube...
  40. ncbi request reprint Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children
    Jennifer R King
    The University of Alabama at Birmingham, Birmingham, Ala, USA
    Antivir Ther 7:267-70. 2002
    ....
  41. ncbi request reprint HIV protease inhibitor ritonavir induces lipoatrophy in male mice
    Eric S Goetzman
    Department of Genetics, University of Alabama at Birmingham, Alabama 35294, USA
    AIDS Res Hum Retroviruses 19:1141-50. 2003
    ..Thus, the effects of ritonavir on serum triglycerides and body composition may be due, at least in part, to an inhibition of PPAR function...
  42. ncbi request reprint Development of a sensitive and specific liquid chromatography/mass spectrometry method for the determination of tenofovir in human plasma
    Chantelle Bennetto-Hood
    The University of Alabama at Birmingham School of Medicine, Division of Clinical Pharmacology, Birmingham, Alabama 35294 0019, USA
    Rapid Commun Mass Spectrom 21:2087-94. 2007
    ..The present method provides an accurate, precise, and sensitive tool for TFV quantitation and was successfully applied to an external proficiency-testing program and pharmacokinetic analysis...
  43. ncbi request reprint Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography
    Michele L Turner
    Division of Clinical Pharmacology, University of Alabama at Birmingham, 1530 3rd Avenue South, VH 116, 35294 0019, Birmingham, AL, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 784:331-41. 2003
    ..Recovery from plasma was consistently high (>80%). This novel HPLC methodology allows us to simultaneously determine plasma concentrations of nine antiretrovirals, including lopinavir, in HIV-infected patients on a single HPLC system...
  44. ncbi request reprint Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria
    Smita A Kshirsagar
    Department of Medicine, Stanford University Medical Center, Stanford, CA, USA
    J Pharmacokinet Pharmacodyn 34:35-55. 2007
    ..Thus, automated methods must be tested rigorously with 'real life' datasets, used with caution, and always in conjunction with clinical reasoning to avoid overlooking a signal in noisy data...
  45. ncbi request reprint Therapeutic drug monitoring in the treatment of HIV-infection
    John G Gerber
    Divisions of Clinical Pharmacology and Infectious Diseases, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Clin Virol 27:117-28. 2003
    ..At this point in time we consider TDM in the treatment of HIV-infection as experimental with significant promise for the future...
  46. ncbi request reprint The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)
    Arlene S Pereira
    Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA
    J Infect Dis 186:198-204. 2002
    ..The antiretroviral effect of APV monotherapy was related to APV concentrations...
  47. ncbi request reprint Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics
    Scott R Penzak
    Department of Pharmacy Practice, Mercer University, Southern School of Pharmacy, Atlanta, Georgia, USA
    J Clin Pharmacol 42:1165-70. 2002
    ..Modulation of intestinal CYP3A4 by grapefruit juice and Seville orange juice did not alter the systemic availability of indinavir. The contribution of presystemic metabolism to indinavir interpatient variability appears to be small...
  48. pmc Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy
    Ighovwerha Ofotokun
    Department of Medicine, Division of Infectious Diseases, Emory University of Medicine, 69 Jesse Hill Jr Drive Atlanta, GA 30303, USA
    J Clin Pharmacol 47:970-7. 2007
    ..74 (90% CI, 0.56-0.98), respectively. No difference in lopinavir/ritonavir plasma concentrations between sexes was demonstrated in this study. However, tenofovir coadministration lowered lopinavir/ritonavir plasma exposure...
  49. doi request reprint Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects
    Daniel R Kuritzkes
    Brigham and Women s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
    J Infect Dis 197:867-70. 2008
    ..27 [95% confidence interval], 1.15-4.49; P = .018). These results support resistance testing before starting antiretroviral therapy...
  50. ncbi request reprint A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Antivir Ther 12:531-41. 2007
    ..Clinical stability has been observed with continued antiretroviral therapy (ART) in the setting of partial virological suppression. The optimal time to switch treatment in patients with low but detectable HIV-1 RNA is not known...
  51. pmc Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants
    Adriana H Tremoulet
    Division of Pharmacology and Drug Discovery, Pediatric Pharmacology Research Unit, University of California San Diego, MC 8214, San Diego, CA 92103 8214, USA
    Antimicrob Agents Chemother 51:4297-302. 2007
    ....
  52. ncbi request reprint Analysis of generic nevirapine products in developing countries
    Scott R Penzak
    JAMA 289:2648-9. 2003
  53. doi request reprint Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 197:1006-10. 2008
    ..There were no significant differences among subgroups with respect to treatment responses. These results demonstrate the potency of efavirenz-containing regimens across a spectrum of pretreatment VLs and CD4 counts...
  54. ncbi request reprint Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects
    David A Parks
    Central West Clinical Research, St Louis, Missouri, USA
    AIDS 21:1373-5. 2007
    ..No clinically significant interaction between the drugs was noted, and the regimen showed good efficacy and tolerability over the course of 48 weeks...
  55. ncbi request reprint Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359
    Courtney V Fletcher
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Infect Dis 189:1176-84. 2004
    ..42%; adjusted odds ratio, 0.43). In this study, a greater proportion of females had HIV RNA levels </=500 copies/mL than did males, which can be attributed to higher concentrations of saquinavir in females than in males...
  56. ncbi request reprint Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects
    Ronald Swanstrom
    University of North Carolina Center for AIDS Research, University of North Carolina, Chapel Hill 27599, USA
    J Infect Dis 190:886-93. 2004
    ..This suggests that the prospective evaluation of PSS to identify regimens that maximize decreases in VL to reduce the probability of virologic rebound could improve antiretroviral treatment...
  57. ncbi request reprint Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study
    David W Haas
    Program for Human Genetics, Vanderbilt University School of Medicine, 345 24th Avenue North, Nashville, TN 37203, USA
    AIDS 18:2391-400. 2004
    ..Efavirenz is metabolized by cytochrome P4502B6 (CYP2B6). We investigated whether polymorphisms in CYP2B6, CYP3A4, CYP3A5, and MDR1 were associated with efavirenz central nervous system side effects and pharmacokinetics...
  58. ncbi request reprint Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results
    Angela Dm Kashuba
    School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    AIDS 19:145-52. 2005
    ..To evaluate fosamprenavir/lopinavir (LPV)/ritonavir (RTV), fosamprenavir/RTV, or LPV/RTV in antiretroviral treatment-experienced patients. Lack of drug interaction data prompted a pharmacokinetic substudy to minimize subject risk...
  59. ncbi request reprint Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance
    Hulin Wu
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Acquir Immune Defic Syndr 39:272-83. 2005
    ..The proposed mathematic models and statistical techniques may provide a framework to simulate and predict antiviral response for individual patients...
  60. ncbi request reprint Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359
    Courtney V Fletcher
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 40:301-6. 2005
    ..Self-reported adherence and saquinavir AUC were significant predictors of virologic response, in this evaluation. These findings provide insight into methods of assessing and improving adherence to antiretroviral regimens...
  61. ncbi request reprint Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals
    David B Clifford
    Washington University School of Medicine, Neurology Department, St Louis, Missouri 63110, USA
    Ann Intern Med 143:714-21. 2005
    ..Efavirenz is a commonly used antiretroviral drug that causes neurologic side effects in more than 50% of patients...
  62. ncbi request reprint Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study
    Heather J Ribaudo
    Statistical Data Analysis Center, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 42:401-7. 2006
    ..Lower plasma efavirenz clearance is associated with a cytochrome P450 2B6 gene (CYP2B6) polymorphism (516G-->T) that is more frequent among African American individuals than among European American individuals...
  63. ncbi request reprint Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness
    David R Bangsberg
    Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, UCSF, San Francisco, California 94143 1372, USA
    AIDS 20:223-31. 2006
    ....
  64. ncbi request reprint Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy
    Gene D Morse
    Department of Pharmacy Practice, University at Buffalo, State University of New York, Amherst 14260, USA
    Lancet Infect Dis 6:215-25. 2006
    ..Current investigation is focused on examining the predictive value of this approach for clinical monitoring...
  65. ncbi request reprint Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence
    Hulin Wu
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, NY 14642, USA
    J Pharmacokinet Pharmacodyn 33:399-419. 2006
    ..But their combinations in viral dynamic modeling significantly predicted virologic response. The HIV dynamic modeling can appropriately capture complicated nonlinear relationships and interactions among multiple covariates...
  66. ncbi request reprint Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial
    Roy M Gulick
    Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY, USA
    JAMA 296:769-81. 2006
    ..Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen...
  67. ncbi request reprint Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood
    Benjamin H Chi
    Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
    HIV Clin Trials 7:263-9. 2006
    ..At present, the only validated method is high-performance liquid chromatography (HPLC), a technique poorly suited for most resource-constrained settings...
  68. ncbi request reprint Design issues in initial HIV-treatment trials: focus on ACTG A5095
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, USA
    Antivir Ther 11:751-60. 2006
    ..We also hope to inform the field regarding issues in choosing composite versus virological endpoints as well as other key considerations in trial design and monitoring...
  69. pmc Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants
    Carmen D Zorrilla
    Obstetrics and Gynecology Department, UPR School of Medicine, P O Box 365067, San Juan, Puerto Rico
    Antimicrob Agents Chemother 51:2208-10. 2007
    ..Two had elevated liver transaminases and amylase. Seven infant adverse events were possibly treatment related (anemia, neutropenia, and hyperbilirubinemia)...
  70. ncbi request reprint Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
    Roy M Gulick
    Weill Medical College of Cornell University, New York, USA
    N Engl J Med 350:1850-61. 2004
    ....
  71. pmc Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186
    John G Gerber
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 47:459-66. 2008
    ..AIDS Clinical Trials Group A5186 examined the safety and efficacy of fish oil plus fenofibrate in subjects not achieving serum TG levels < or =200 mg/dL with either agent alone...
  72. ncbi request reprint Antiretroviral drug content in products from developing countries
    Scott R Penzak
    Department of Pharmacy, Warren G Magnuson Clinical Center, Bethesda, Maryland, USA
    Clin Infect Dis 38:1317-9. 2004
    ..We analyzed 6 antiretroviral medications from 4 international sources for drug content. The active ingredient in tested drug products was within 15% of the labeled amount (range, -12% to +15%) for drugs that were properly stored...

Research Grants3

  1. INTEGRATE/PHARMACOKINETIC/ANTIRETROVIRUS RESISTANCE TEST
    Edward Acosta; Fiscal Year: 2006
    ..abstract_text> ..